NDAORALCAPSULE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
COXANTO (oxaprozin) by Teva is cyclooxygenase inhibitors [moa]. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COXANTO (oxaprozin) is an oral nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain. It is indicated for rheumatoid arthritis and osteoarthritis, providing symptomatic relief of signs and symptoms in patients with chronic inflammatory joint conditions.
Growth
Recent 2023 approval positions this in early growth phase with opportunity to build market share; expect expansion of commercial teams including field sales and managed care roles.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Drug-drug Interaction Study of FYU-981 and Oxaprozin
Started Nov 2017
12 enrolled
Healthy
Career Relevance
Working on COXANTO offers career exposure in a competitive, cost-sensitive arthritis market requiring strong market access and managed care negotiation skills. The early-stage growth lifecycle and modest clinical differentiation position this role as suitable for professionals developing expertise in NSAID positioning and value-based contracting rather than cutting-edge drug development.
Brand Manager
Worked on COXANTO at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.